Huy N Trinh
Overview
Explore the profile of Huy N Trinh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
60
Citations
975
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kudaravalli S, Huang D, Yeh M, Trinh L, Tsai P, Hsu Y, et al.
J Hepatol
. 2024 Jun;
81(1):33-41.
PMID: 38906621
Background & Aims: Oral antiviral therapy with nucleos(t)ide analogues (NAs) for chronic hepatitis B (CHB) is well-tolerated and lifesaving, but real-world data on utilization are limited. We examined rates of...
2.
Ogawa E, Won Jun D, Toyoda H, Hsu Y, Yoon E, Ahn S, et al.
Aliment Pharmacol Ther
. 2023 Oct;
59(2):239-248.
PMID: 37882252
Background: Data on patients switched to tenofovir alafenamide (TAF) from nucleos(t)ide analogues (NUCs) other than tenofovir disoproxil fumarate are limited. Aims: To assess the treatment and renal/bone safety outcomes following...
3.
Wong Y, Tran S, Huang C, Hsu Y, Preda C, Toyoda H, et al.
Hepatol Int
. 2023 Jun;
17(5):1150-1161.
PMID: 37273170
Introduction: Current guidelines discourage the use of direct-acting antiviral (DAA) containing protease-inhibitor (PI) in advanced HCV cirrhosis. We aimed to compare the real-world tolerability of PI vs. non-PI DAA regimens...
4.
Huang D, Tran A, Yeh M, Yasuda S, Tsai P, Huang C, et al.
Hepatology
. 2023 May;
78(5):1558-1568.
PMID: 37184202
Background And Aims: HCC risk in chronic hepatitis B (CHB) is higher in the indeterminate phase compared with the inactive phase. However, it is unclear if antiviral therapy reduces HCC...
5.
Trinh L, Vinh M, Choudhary A, Levitt B, Kutty G, Shieh E, et al.
Medicine (Baltimore)
. 2022 Sep;
101(37):e30577.
PMID: 36123845
Endoscopic screening is used widely to minimize the rates of colorectal cancer cases and deaths. During highly virulent infectious disease pandemics such as the coronavirus disease 2019 (COVID-19) pandemic, it...
6.
Huang D, Lee D, Le M, Le A, Yeo Y, Trinh H, et al.
Dig Dis
. 2022 Sep;
41(1):115-123.
PMID: 36070707
Background: A substantial number of patients who do not meet treatment criteria for chronic hepatitis B (CHB) later develop adverse outcomes such as cirrhosis and hepatocellular carcinoma (HCC). Our aim...
7.
Nguyen M, Atsukawa M, Ishikawa T, Yasuda S, Yokohama K, Trinh H, et al.
Am J Gastroenterol
. 2021 Jun;
116(6):1264-1273.
PMID: 34074829
Introduction: Entecavir (ETV) and tenofovir alafenamide (TAF) are both first-line hepatitis B virus (HBV) therapies, but ETV-to-TAF switch outcome data are limited. We aimed to assess outcomes up to 96...
8.
Bernstein D, Trinh H, Schiff E, Smith C, Mospan A, Zink R, et al.
Dig Dis Sci
. 2021 Jun;
67(6):2637-2645.
PMID: 34059991
Background: Nucleos(t)ide analogues, with a proven record of safety and efficacy, have been the therapy of choice for over a decade for the treatment of chronic hepatitis B. The approval...
9.
Toyoda H, Leong J, Landis C, Atsukawa M, Watanabe T, Huang D, et al.
Hepatology
. 2021 Mar;
74(2):656-666.
PMID: 33706421
Background And Aims: Real-world data for treatment effectiveness and renal outcomes in chronic hepatitis B (CHB) patients who were switched to the new and safer prodrug tenofovir alafenamide (TAF) from...
10.
Tseng T, Choi J, Nguyen M, Peng C, Siakavellas S, Papatheodoridis G, et al.
Hepatol Int
. 2021 Feb;
15(1):105-113.
PMID: 33547557
Background And Aims: Fibrosis-4 (FIB-4) index is a HCC predictor in chronic hepatitis B (CHB) patients. However, little is known about whether FIB-4 helps identify non-cirrhotic CHB patients with minimal...